middle.news
Vita Life Sciences Eyes 16% Revenue Growth Despite China Setback
3:51pm on Tuesday 17th of June, 2025 AEST
•
Healthcare
Read Story
Vita Life Sciences Eyes 16% Revenue Growth Despite China Setback
3:51pm on Tuesday 17th of June, 2025 AEST
Key Points
H1 2025 sales guidance of $45.0m-$46.0m, up 14-16% from prior year
Pre-tax profit expected between $6.2m and $6.7m, slightly higher than H1 2024
Core markets Australia, Malaysia, and Singapore show robust growth
Sales in China decline compared to prior period despite new distributor efforts
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vita Life Sciences (ASX:VLS)
OPEN ARTICLE